Synapse - Alexander Lesokhin

Results (381)

Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma

Research Letter

Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
Clinical Lymphoma, Myeloma and Leukemia (2020)

Fulltext@MSK | Save

Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Raje, N. S.; Jakubowiak, A.; Gasparetto, C.; Cornell, R. F.; Krupka, H. I.; Navarro, D.; Forgie, A. J.; Udata, C.; Basu, C.; Chou, J.; more...
Blood (2019)

Fulltext@MSK | Save

VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis

Meeting Abstract

Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
Blood (2019)

Fulltext@MSK | Save

An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma

Meeting Abstract

Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
Blood (2019)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma

Meeting Abstract

Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
Blood (2019)

Fulltext@MSK | Save

MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy

Meeting Abstract

Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
Blood (2019)

Fulltext@MSK | Save

Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma

Meeting Abstract

Bal, S.; Landau, H.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Lesokhin, A. M.; Lendvai, N.; more...
Biology of Blood and Marrow Transplantation (2019)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study